Publicaciones

  • de Aberasturi AL, Calvo A. TMPRSS4: an emerging potential therapeutic target in cancer. Br J Cancer 2015; 112: 4-8. IF: 4.836. Lugar: 34/211 Oncology. Primer cuartil.

  • Bleau AM, Freire J, Pajares MJ, Zudaire I, Anton I, Nistal-Villan E, Redrado M, Zandueta CN, Garmendia I, Ajona D, Blanco D, Pio R, Lecanda F, Calvo A, Montuenga LM. New syngeneic inflammatory-related lung cancer metastatic model harboring double KRAS/WWOX alterations. International Journal of Cancer 2014; 135: 2516-2527. IF: 5.085. Lugar: 31/211 Oncology. Primer cuartil.

  • Agorreta J, Hu J, Liu D, Delia D, Turley H, Ferguson DJ, Iborra F, Pajares MJ, Larrayoz M, Zudaire I, Pio R, Montuenga LM, Harris AL, Gatter K, Pezzella F. TRAP1 regulates proliferation, mitochondrial function, and has prognostic significance in NSCLC. Mol Cancer Res. 2014; 12: 660-9. IF: 4.380. Lugar: 44/211 Oncology. Primer cuartil.

  • Larzabal L, de Aberasturi AL, Redrado M, Rueda P, Rodriguez MJ, Bodegas ME, Montuenga LM, Calvo A. TMPRSS4 regulates levels of integrin α5 in NSCLC through miR-205 activity to promote metastasis. Br J Cancer 2014; 110: 764-74. IF: 4.836. Lugar: 34/211 Oncology. Primer cuartil.

  • Romero OA, Torres-Diz M, Pros E, Savola S, Gomez A, Moran S, Saez C, Iwakawa R, Villanueva A, Montuenga LM, Kohno T, Yokota J, Sanchez-Cespedes M. MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1. Cancer Discov. 2014; 4: 292-303. IF: 19.453. Lugar: 5/211 Oncology. Primer decil.

  • Larrayoz M, Pio R, Pajares MJ, Zudaire I, Ajona D, Casanovas O, Montuenga LM,Agorreta J. Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype. EMBO Mol Med 2014; 6: 539-550. IF: 8.665. Lugar: 9/123 Medicine, Research & Experimental. Primer decil.
    ABSTRACT CORTESÍA DE PUBMED

  • Larzabal L, de Aberasturi AL, Redrado M, Rueda P, Rodriguez MJ, Bodegas ME, Montuenga LM, Calvo. TMPRSS4 regulates levels of integrin α5 in NSCLC through miR-205 activity to promote metastasis. Br J Cancer 2014; 110: 764-774. IF: 4.836. Lugar: 34/211 Oncology. Primer cuartil.

  • Freire J, Ajona D, de Biurrun G, Agorreta J, Segura V, Guruzeaga E, Bleau AM, Pío R, Blanco D, Montuenga LM. Silica-induced chronic inflammation promotes lung carcinogenesis in the context of an immunosuppressive microenvironment. Neoplasia 2013; 15: 913-924. IF: 5.398. Lugar: 28/203 Oncology. Primer cuartil. 

  • Corrales L, Ajona D, Rafail S, Lasarte JJ, Riezu-Boj JI, Lambris JD, Rouzaut A, Pajares MJ, Montuenga LM, Pío R. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. Journal of Immunology 2012; 189: 4674-4683. IF: 5.520. Lugar: 24/137 Immunology. Primer cuartil. 

  • Ponz-Sarvisé M, Nguewa PA, Pajares MJ, Agorreta J, Lozano MD, Redrado Pío R, Behrens C, Wistuba I, García-Franco, CE, García-Foncillas J, Montuenga, LM, Calvo A, Gil-Bazo I. Inhibitor of differentiation-1 is a novel prognostic factor in NSCLC patients with adenocarcinoma histology and contributes to therapy resistance. Clinical Cancer Research 2011; 17: 4155-4166. IF: 8.722; Lugar: 12/211 Oncology. Primer decil.

  • Larzabal L, Nguewa PA, Pio R, Blanco D, Sanchez B, Rodríguez MJ, Pajares MJ, Catena R, Montuenga LM, Calvo A. Overexpression of TMPRSS4 in non-small cell lung cancer is associated with poor prognosis in patients with squamous histology. Br J Cancer. 2011;105: 1608-14. IF: 5.042; Lugar: 33/196 Oncology. Primer cuartil.

  • Serrano D, Bleau AM, Fernandez-Garcia I, Fernandez-Marcelo T, Iniesta P, Ortiz-de-Solorzano C, Calvo A. Inhibition of telomerase activity preferentially targets aldehyde dehydrogenase-positive cancer stem-like cells in lung cancer. Mol Cancer. 2011; 10: 96. IF: 3.993; Lugar: 49/196 Oncology. Segundo cuartil.

  • Gonzalez-Moreno O, Boque N, Redrado M, Milagro F, Campion J, Endermann T, Takahashi K, Saito Y, Catena R, Schomburg L, Calvo A. Selenoprotein-P is down-regulated in prostate cancer, which results in lack of protection against oxidative damage. Prostate 2011; 71: 824-34. IF: 3.485; Lugar: 14/73 Urology and Nephrology. Primer cuartil.

  • de Miguel FJ, Sharma RD, Pajares MJ, Montuenga LM, Rubio A, Pío R. Identification of alternative splicing events regulated by the oncogenic factor SRSF1 in lung cancer. Cancer Research 2014; 74: 1105-1115. IF: 9.284. Lugar: 10/203 Oncology. Primer decil. 

    ABSTRACT CORTESÍA DE PUBMED


Dr. Luis Montuenga.

Más información:

Contactar

Contacto:
Marisol Ripa
Avda. Pío XII, 55
31008 Pamplona
España

(+34) 948 194 700 Ext. 1010
msripa@unav.es